Inhibition of Tumor Growth Using Salmonella Expressing Fas Ligand

Intravenous administration of bacteria leads to their accumulation in tumors and to sporadic tumor regression. We therefore explored the hypothesis that Salmonella typhimurium engineered to express the proapoptotic cytokine Fas ligand (FasL) would exhibit enhanced antitumor activity. Immunocompetent mice carrying tumors derived from syngeneic murine D2F2 breast carcinoma or CT-26 colon carcinoma cells were treated intravenously with FasL-expressing S. typhimurium or with phosphate-buffered saline (PBS; control). Treatment with FasL-expressing S. typhimurium inhibited growth of primary tumors by an average of 59% for D2F2 tumors and 82% for CT-26 tumors (eg, at 25 days after initial treatment, mean volume of PBS-treated CT-26 colon carcinomas = 1385 mm3 and of S. typhimurium FasL-treated CT-26 tumors = 243 mm3, difference = 1142 mm3, 95% confidence interval = 800 mm3 to 1484 mm3, P < .001). Pulmonary D2F2 metastases (as measured by lung weight) were reduced by 34% in S. typhimurium FasL-treated mice compared with PBS-treated mice. FasL-expressing S. typhimurium had similar effects on growth of murine B16 melanoma tumors in wild-type mice but not in lpr/lpr mice, which lack Fas, or in mice with disrupted host inflammatory responses. Antitumor activity was achieved without overt toxicity. These preclinical results raise the possibility that using attenuated S. typhimurium to deliver FasL to tumors may be an effective and well-tolerated therapeutic strategy for some cancers.

[1]  John Calvin Reed,et al.  Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth , 2007, Proceedings of the National Academy of Sciences.

[2]  M. Loeffler,et al.  Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. , 2006, The Journal of clinical investigation.

[3]  A. Yahagi,et al.  Fas Ligand Induces Cell-Autonomous IL-23 Production in Dendritic Cells, a Mechanism for Fas Ligand-Induced IL-17 Production1 , 2005, The Journal of Immunology.

[4]  M. Sznol,et al.  Systemic Administration of an Attenuated, Tumor-Targeting Salmonella typhimurium to Dogs with Spontaneous Neoplasia: Phase I Evaluation , 2005, Clinical Cancer Research.

[5]  A. Thorburn,et al.  Death receptor-induced cell killing. , 2004, Cellular signalling.

[6]  O. Janssen,et al.  Slowly getting a clue on CD95 ligand biology. , 2003, Biochemical pharmacology.

[7]  S. Rosenberg,et al.  Antitumor Effects in Mice of the Intravenous Injection of Attenuated Salmonella Typhimurium , 2002, Journal of immunotherapy.

[8]  Hans Wolf-Watz,et al.  Molecular characterization of type III secretion signals via analysis of synthetic N‐terminal amino acid sequences , 2002, Molecular microbiology.

[9]  J. Tschopp,et al.  FAS Engagement Induces the Maturation of Dendritic Cells (Dcs), the Release of Interleukin (Il)-1β, and the Production of Interferon γ in the Absence of IL-12 during Dc–T Cell Cognate Interaction , 2000, The Journal of experimental medicine.

[10]  P. Fink,et al.  Fas Ligand Costimulates the In Vivo Proliferation of CD8+ T Cells1 , 2000, The Journal of Immunology.

[11]  X. Luo,et al.  Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. , 2000, The Journal of infectious diseases.

[12]  M. Levine,et al.  Optimization of Plasmid Maintenance in the Attenuated Live Vector Vaccine Strain Salmonella typhiCVD 908-htrA , 1999, Infection and Immunity.

[13]  F. Dallegri,et al.  Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. , 1999, Journal of immunology.

[14]  E. Nabel,et al.  Gene transfer of Fas ligand induces tumor regression in vivo. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[15]  H. Maeda,et al.  Polymorphism of murine Fas ligand that affects the biological activity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Weller,et al.  Local Fas/APO‐1 (CD95) ligand‐mediated tumor cell killing in vivo , 1995, European journal of immunology.

[17]  T. Malek,et al.  Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. , 1993, Journal of immunology.

[18]  S. Nagata,et al.  Lethal effect of the anti-Fas antibody in mice , 1993, Nature.

[19]  G. Dougan,et al.  Expression of human IL-1 beta in Salmonella typhimurium. A model system for the delivery of recombinant therapeutic proteins in vivo. , 1992, Journal of immunology.

[20]  D. Euhus,et al.  Tumor measurement in the nude mouse , 1986, Journal of surgical oncology.

[21]  Bill Broyles Notes , 1907, The Classical Review.

[22]  John Mao,et al.  Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.